The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
ApexOnco Front Page
Recent articles
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
PD-(L)1 x VEGF bispecifics prove a big draw.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Some big deals in the second quarter have raised hopes that takeouts are back.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
